Barclays Rates Nuvalent (NUVL) hold, $124 Price Target
Barclays has adjusted its outlook on Nuvalent Inc, setting a hold rating and a $124.0 price target, a 0.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barclays rated Nuvalent Inc ($NUVL) "hold" with a $124 price target on June 10, 2026.
Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).
NUVL
Nuvalent Inc
Key Points
- Barclays analyst Etzer Darout lowered the rating on Nuvalent Inc to hold on June 10, 2026, setting a price target of $124.0.
- Barclays's $124 price target implies 0.61% upside from Nuvalent Inc's ($NUVL) current $123.25 share price.
- Nuvalent Inc shares recently traded around $123.25, hovering near its 52-week high of $123.99.
- Bernstein also covers the stock with a Market Perform rating and a price target of $124.0 as of June 24, 2026.
Get $NUVL trade alerts by text
We text you when insiders, Congress or big funds trade $NUVL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent Inc alert may contain errors. Disclosures
Barclays Adjusts View on Nuvalent Inc
On June 10, 2026, Barclays analyst Etzer Darout lowered the rating on Nuvalent Inc (NGM: NUVL) to a hold stance, establishing a price target of $124.0. The update reflects a shifting perspective from the firm as the biotechnology company continues its clinical-stage pipeline work.
Nuvalent Stock Price and Market Context
Nuvalent shares recently changed hands at $123.25, sitting close to the top of its 52-week range of $71.13 to $123.99. The company carries a market capitalization of roughly $9.81 billion. Because the clinical-stage firm is not currently profitable, it has no meaningful price-to-earnings ratio.
$NUVL price target
Nuvalent Inc daily closes and this analyst's $124 target. Not advice.
Analysts Set New Price Targets
Other Wall Street firms have also updated their outlooks on the biotechnology developer. On June 24, 2026, Bernstein issued a downgrade action, rating the stock at Market Perform with a price target of $124.0, down from its prior target of $172.0. Across the broader analyst community, Nuvalent holds a consensus recommendation of hold, backed by nine analyst opinions and a mean price target of $124.0.
About Nuvalent Inc
Headquartered in Cambridge, Massachusetts, Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating targeted therapies for cancer patients. Its pipeline includes product candidates such as Zidesamtinib for non-small cell lung cancer, Neladalkib for ALK-positive tumors, and NVL-330 targeting HER2-driven tumors. The company aims to overcome treatment resistance and reduce central nervous system side effects.
What to Watch at NUVL
Investors will be tracking subsequent analyst notes and upcoming corporate updates from Nuvalent to gauge clinical trial progress for its lead drug candidates. Additional price target shifts or rating changes from major investment banks will provide further direction for the stock.
Related Filing Alerts
Source: Barclays's rating change on $NUVL (Jun 10, 2026). Written by software, not financial advice. How we make alerts